A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. - Wikidata - wikimedia - TriplyDB

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.

http://www.wikidata.org/entity/Q33390586

about

Overview of current immunotherapeutic strategies for glioma Immunologic characterization of a rhesus macaque H1N1 challenge model for candidate influenza virus vaccine assessment.Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation.Controversies in the adjuvant therapy of high-grade gliomas.Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors.Function and mechanism of toll-like receptors in cerebral ischemic tolerance: from preconditioning to treatment.Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma Poly-IC preconditioning protects against cerebral and renal ischemia-reperfusion injury.Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity.Immunization route dictates cross-priming efficiency and impacts the optimal timing of adjuvant delivery Trial Watch: Experimental Toll-like receptor agonists for cancer therapy Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling.A unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses.Prioritization schema for immunotherapy clinical trials in glioblastoma.Recent advances and future of immunotherapy for glioblastoma.Smac mimetics and innate immune stimuli synergize to promote tumor death Stimulating natural killer cells to protect against cancer: recent developments.Polypeptides and polyaminoacids in drug delivery.A novel treatment for glioblastoma: integrin inhibition.State of the art and perspectives in the treatment of glioblastoma.Vaccine adjuvant uses of poly-IC and derivatives.In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.In situ vaccination for the treatment of cancer.Designing therapeutic cancer vaccines by mimicking viral infections.Biological Response Modifier in Cancer Immunotherapy.Toward RNA nanoparticle vaccines: synergizing RNA and inorganic nanoparticles to achieve immunopotentiation.Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer.Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma.Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma.A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.Vaccination in the immunotherapy of glioblastoma.WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways.Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.

P2860

Q26776345-FD324C8D-FAB7-4C67-A288-BDAFFE3ED3AD Q30367637-538A4E83-49B7-42B4-829C-A8CA3848C2DE Q31152190-3F68F02A-4A1D-4EB9-ADB2-4F7C2EAD38D4 Q33394265-ACD0B9D3-38CE-458E-BCDC-3579A5A9D98B Q34657329-031C9017-11DC-4D51-B1A3-964C27BDE24A Q35167156-EEE5686A-2C77-42A4-940C-B9B606DBAA9F Q35575846-133BCECE-0CFC-44D4-A6ED-83B182584BC7 Q35669097-4978871F-76F3-4EC7-BBDC-C3C6F59040BC Q35701142-EDA64234-E22C-4AAA-B391-BE2FB7B2FF38 Q35738331-4953CF1E-AAE4-4A48-9A06-195C9A02426A Q35768825-4BF6AC3B-AE56-412B-A8D9-1866C5EFC778 Q35928216-69C083DD-63D0-481F-A012-0001477A6CDE Q36194849-BCB138A3-D730-48C2-A2BD-8DF789AA821F Q36245506-29E4D936-550A-4A00-BCF0-995318D538A2 Q36315857-CD41E2F3-A87D-41FF-82FE-497C40D63950 Q36347457-26C1F96B-D2C2-40F0-9760-13F58CEADCD1 Q36511199-7A7ACE70-E8B4-4C65-BDEA-2C37BC9692E0 Q37078999-8E4F2A0E-2C1A-4EE3-BF6B-D0B0907FE6A8 Q37239071-6CB3112E-EB8A-4069-978C-7455FE6F2D2B Q37270377-D1812FA4-0701-428F-A469-63C37935E229 Q37877269-98F91A21-3308-44AE-BE50-71ED67C2C29A Q37975554-EA844A58-8C43-44B0-A118-015A672430E9 Q37997092-F12E48F9-DB79-40BE-8764-48E1422BC575 Q38233067-7F6D590D-47AC-434F-A7AF-95F9A22F5790 Q38259510-BA18AE4A-8546-4468-932A-BF622FBD786B Q38657642-07431071-F6D8-4A7C-A753-7A3D1F65F2E0 Q38727470-1B4B2217-25CF-4514-BC64-07308D0D2571 Q38800011-25D06184-7C53-4E7F-9BBD-4C900F5D3179 Q38848213-D6ABEF1A-D8FF-41C7-8591-98A1A2561745 Q38867794-03ECB4C6-790C-4C4B-A2EA-2BFE38DCA476 Q39142289-F6A99668-DF07-4D8C-A550-8191D93F05AD Q39196377-273D9637-D647-4066-BBA7-5FCDA63521A9 Q39198219-639B5993-4448-4B4E-AF65-395D6DEBBE4A Q39236500-52830310-94F4-4CFC-BB58-941DB2E20FD4 Q45073466-1689CD1C-E3EE-4BD2-B976-DB7CA38B0675 Q46189367-2ED3636B-9D12-4132-80AD-9413EEDA0F8F Q47583155-1EBBB992-BA5B-4D2E-857F-A9CB57A0750B Q48222390-8A5F8F31-A152-4301-BC5A-78B3AEDE0380 Q52590668-7D76A44E-1EBA-4B58-B065-ECB0532F89D6 Q55257766-FAAD0CF2-F019-40F1-A804-607F425F3F55

P2860

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.

http://www.wikidata.org/entity/Q33390586

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A multi-institution phase II s ...... newly diagnosed glioblastoma.

@ast

A multi-institution phase II s ...... newly diagnosed glioblastoma.

@en

type

label

A multi-institution phase II s ...... newly diagnosed glioblastoma.

@ast

A multi-institution phase II s ...... newly diagnosed glioblastoma.

@en

prefLabel

A multi-institution phase II s ...... newly diagnosed glioblastoma.

@ast

A multi-institution phase II s ...... newly diagnosed glioblastoma.

@en

P1433

Q33390586-BF3F8EAD-4EB1-4354-AFDF-743F689B33EA

P1476

Q33390586-A6676960-0467-4C9F-9A10-687CA45C5816

P2093

Q33390586-2ED485B7-940E-40B8-92F2-97E64086C57F

Q33390586-5393697F-E3D4-4348-B8A0-88EDF3D8A999

Q33390586-8CE22B83-FC3D-4DD6-A520-EB8961732606

Q33390586-C3FC3831-6518-484E-8CEB-5C67A61CB8A9

Q33390586-CB52EB67-9046-475B-A18A-025C5771C969

Q33390586-CC72E04C-B0A7-40EA-B6C3-71196E6CF616

Q33390586-CCA53F9A-76C6-431D-8B9D-D344829B5AEA

Q33390586-ED44FBB8-E0F0-475B-B6BB-6F67058E7288

P2860

Q33390586-25B72EB7-E017-4D9B-9236-D2496892722F

Q33390586-35ED15E2-CDBA-48F1-B79A-53F1353FAE6F

Q33390586-41A8CD4C-0B3B-4DCF-9F44-1EC3B7924E77

Q33390586-41B798F5-18C5-4CFE-865B-9478EB673F8C

Q33390586-53A64F9A-5A38-40D5-841F-8A347EEF429C

Q33390586-7EF1970D-07DA-4DF9-B7BD-04692CAAFEAD

Q33390586-8080B700-5E49-4A51-9229-14D124C48895

Q33390586-8AD5C6CB-8564-4FAB-B27C-734618B54BB8

Q33390586-A2FC10AA-48DA-4428-98F6-272C164836EA

Q33390586-BB73CF83-31FA-49C8-B850-6F6D2CF6FAB5

P304

Q33390586-D30A3F07-9E90-4B42-B0D5-92104A40C68A

P31

Q33390586-149249D0-EA23-4049-A2F1-47C5135B53E2

P356

Q33390586-498F0ACA-9324-45EE-B497-CC295D341481

P433

Q33390586-1478219B-01AA-455B-896B-B1F2FCC231AE

P478

Q33390586-DFDEA7B4-0623-4FDD-B1B6-BE63820108BB

P50

Q33390586-7EFB0667-C4A8-47D7-B5B9-57EF1B6EA791

P577

Q33390586-8CA9802C-A2E7-4CCC-843D-5A08C5943411

P5875

Q33390586-120E2720-4F8B-4B1A-866C-460709B42F77

P698

Q33390586-41A00893-E869-4C9E-94E1-05821D9186F4

P921

Q33390586-9393A801-3FA2-40E9-A27B-B80176D572F7

P932

Q33390586-487B0B84-60BA-44D7-8A1E-B2A98ADD422B

P356

P1433

P1476

A multi-institution phase II s ...... newly diagnosed glioblastoma.

@en

P2093

Andres M Salazar

http://www.w3.org/2001/XMLSchema#string

David M Peereboom

http://www.w3.org/2001/XMLSchema#string

Glenn J Lesser

http://www.w3.org/2001/XMLSchema#string

Marc C Chamberlain

http://www.w3.org/2001/XMLSchema#string

Serena Desideri

http://www.w3.org/2001/XMLSchema#string

Stuart A Grossman

http://www.w3.org/2001/XMLSchema#string

Tracy T Batchelor

http://www.w3.org/2001/XMLSchema#string

Xiaobu Ye

http://www.w3.org/2001/XMLSchema#string

P2860

Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses.

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.

A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).

P304

1071-1077

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOQ071

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Myrna Rosenfeld

P577

2010-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45113466

http://www.w3.org/2001/XMLSchema#string

P698

20615924

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

3018929

http://www.w3.org/2001/XMLSchema#string